Biosimilars

The AJMC^® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Retinal condition | Image Credit: Yakobchuk Olena - stock.adobe.com

Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD

By Cameron Santoro

October 30th 2024

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).

health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com

Exploring the Complexities of Biosimilars and Interchangeability

By Skylar Jeremias

October 30th 2024

Cost of health care | Image Credit: Scott Hales - stock.adobe.com

Biosimilars Expand Access and Reduce Costs in Oncology, Immunology

By Cameron Santoro

October 28th 2024

Market share increase | Image Credit: Kiattisak - stock.adobe.com

Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends

By Cameron Santoro

October 15th 2024

FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

By Skylar Jeremias

October 11th 2024

Continuing Medical Education

October 30th 2024

Managed Care Pharmacy: A Plan for the Future and How Pharmacists Are Leading the Way

0.5 Credits / General Pharmacy

More News

Evidence From Drug Manufacturers and Patient Access

May 10th 2017

Evidence From Drug Manufacturers and Patient Access

Off-Label Communications: What It Means for Stakeholders

May 10th 2017

Off-Label Communications: What It Means for Stakeholders

February 27th 2017

What We're Reading: Single-Payer Plan in Calif.; New Mexico Biosimilar Bill; and Shared Decision Making

October 10th 2016

Biosimilars and Interchangeability: Evolving Understanding and Regulations

Laura Joszt, MA

The FDA has already approved 4 biosimilars in the United States, but there remains a lot of uncertainty surrounding some of the legislation and regulation.

October 7th 2016

5 Key Takeaways From AMCP Nexus 2016

Laura Joszt, MA

Specialty pharmacy pipelines, healthy behaviors, and regulation took the stage at the Academy of Managed Care Pharmacy (AMCP)’s 2016 Nexus conference, which was held October 3-6 in National Harbor, Maryland.

September 28th 2016

Participating Faculty

September 23rd 2016

UnitedHealth's 2017 Formulary to Support Generic and Biosimilar Drugs

Surabhi Dangi-Garimella, PhD

UnitedHealth has posted a presentation on its website that provides an update to its pharmacy benefits and prescription drug lists for 2017.

August 8th 2016

PBMs Create a Path for Me-Too Drugs, Biosimilars on Their Oncology Formulary

Surabhi Dangi-Garimella, PhD

Pharmacy benefit managers (PBMs) and large employer organizations are taking measures to save healthcare costs in 2017, and for PBMs, formulary exclusions is a fool-proof tactic.

July 6th 2016

What We're Reading: VA Healthcare Operations Still Require "Urgent Reform"

What we're reading, July 6, 2016: the Department of Veterans Affairs has made progress, but still has a long way to go; court upholds 6-month delay for biosimilars; and Apple promotes organ donation with iPhone app.

June 24th 2016

What We're Reading: How Brexit Could Impact Drug Regulation

What we're reading, June 24, 2016: Britain's decision to leave the European Union will impact drug regulation; Supreme Court decision derails California proposal to allow illegal immigrants to buy health insurance; and lawmakers look to reduce exclusivity period for biologics.

June 21st 2016

Industry Insight on the Challenges With Developing and Adopting Biosimilars

Surabhi Dangi-Garimella, PhD

At the annual meeting of The Community Oncology Alliance, oncologists sat through a crash course on biosimilars that was rendered by experts from the pharmaceutical industry.

Dr Aimee Tharaldson Expects the Biosimilar Approval Process to Pick Up Speed

June 10th 2016

Dr Aimee Tharaldson Expects the Biosimilar Approval Process to Pick Up Speed

The process for approving biosimilars has been moving slowly, but Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, foresees them as having the potential to lower costs for the industry and hopes the approval process will pick up speed.

Dr Pamela Becker: Bar Is Set Very High to Meet Biosimilar Definition

May 25th 2016

Dr Pamela Becker: Bar Is Set Very High to Meet Biosimilar Definition

The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived differences, according to Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine.

May 5th 2016

Adoption of Biosimilars: Prescriber, Pharmacy and Payer Perspectives

May 3rd 2016

Dr Jeremy Schafer Discusses Paying for Biosimilars and Patient Education

Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value, discussed a number of important topics regarding biosimilars, including how he expects the US will have an easier time approving biosimilars and the importance of patient education about biosimilars.

April 19th 2016

What We're Reading: Theranos Now Subject of a Criminal Investigation

What we're reading, April 19, 2016: blood-testing laboratory Theranos is now facing a criminal investigation; biosimilars may not be cheaper than brand name biologics for some seniors; and stigma and misconceptions remain regarding palliative care.

Dr Jeremy Schafer Discusses the Importance of Immunogenicity of Biosimilars

April 19th 2016

Dr Jeremy Schafer Discusses the Importance of Immunogenicity of Biosimilars

The FDA recently approved the biosimilar infliximab and found that from an immunogenicity profile it was more or less similar, which is important for payers and providers, explained Jeremy Schafer, PharmD, MBA, vice president and director of specialty solutions at Precision For Value.

April 15th 2016

Industry Insight on the Challenges With Developing and Adopting Biosimilars

Surabhi Dangi-Garimella, PhD

Pharmaceutical industry experts provide an overview of the highly complex biosimilar development process at The Community Oncology Conference: Innovation in Cancer Care, held in Orlando, Florida.

April 13th 2016

Adoption of Biosimilars: Prescribers, Pharmacy and Payer Perspectives

April 1st 2016

NCCN Has Faith in the Potential of Biosimilars

Surabhi Dangi-Garimella, PhD

While these "generic" biologicals have been deemed to have the potential to create competition and result in healthcare savings-although not to the extent of generic products-technical issues with manufacturing these products have troubled drug manufacturers.

Dr Pamela Becker Says the US Is "Just Scratching the Surface" for Biosimilars

April 1st 2016

Dr Pamela Becker Says the US Is "Just Scratching the Surface" for Biosimilars

Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.

March 31st 2016

IMS Health Predicts Significant Growth of Biosimilars by 2020

Surabhi Dangi-Garimella, PhD

According to IMS Health, increased penetration and acceptance of biosimilars in Europe and in the United States can result in $110 billion in total savings to the 2 healthcare systems.

March 17th 2016

Biosimilars Important in Management of Neutropenia

Recent analysis supports the potential importance of using biosimiliars of granulocyte colony stimulating factor to manage neutropenia affecting post-chemotherapy and post-op patients.

February 18th 2016

What We're Reading: Some Clinical Trial Results Are Never Disclosed

What we're reading, February 18, 2016: one-third of clinical trial results are never published; Sandoz challenges rule for notices of biosimilar launches; and hepatitis C combination drug could reduce treatment to just 4 weeks.

February 5th 2016

A New Biosimilar to Remicade in the Fray

Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.

January 8th 2016

What We're Reading: Report Reveals Full ACA Enrollment So Far

What we're reading, January 8, 2016: HHS releases report with full Obamacare enrollment information for all 50 states and the District of Columbia; the expansion of the biosimilars in 2016; and promising Ebola treatment found not effective.

January 1st 2016

5 Things to Know About Biosimilars in the New Year

Surabhi Dangi-Garimella, PhD

An update on where the field of biosimilars currently stands.

December 28th 2015

Post Test: Clinical and Managed Care Implications of Biosimilars: Evaluating the Science and Challenges to Uptake

December 22nd 2015

Top 10 Articles from Evidence-Based Oncology for the Year 2015

Surabhi Dangi-Garimella, PhD

The most read articles in The American Journal of Managed Care's Evidence-Based Oncology ranged from personal narratives to healthcare policy issues that impact the broader population.

Dr Joe V. Selby on Biosimilar Research

November 26th 2015

Dr Joe V. Selby on Biosimilar Research

The Patient-Centered Outcomes Research Institute (PCORI) will approach biosimilar research the way it does research on anything else, but there is the added element of finding the right timing, said Joe V. Selby, MD, MPH, executive director of PCORI.

...

12 13 14 15 16 17 18 19 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions